Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Antineoplastic Agents

All Drugs and Chemicals

Paclitaxel

Albumin-Bound Paclitaxel

Carboplatin

Imetelstat

Motesanib diphosphate

Tubulin Modulators

Antimitotic Agents

Protein Kinase Inhibitors

Enzyme Inhibitors

All subjects on this treatment arm will receive a standard paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200mg/m2 and carboplatin at AUC of 6mg/mL x min by Calvert formula) on day 1 of each 3 week cycle + - 3 days for a maximum of 6 cycles and placebo 125mg QD orally

All subjects on this treatment arm will receive a standard paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200mg/m2 and carboplatin at AUC of 6mg/mL x min by Calvert formula) on day 1 of each 3 week cycle + - 3 days for a maximum of 6 cycles and AMG 706 125mg QD orally.

AMG 706

placebo

200mg/m2 on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles

paclitaxel

AUC of 600mg/mL x min by Calvert formula on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles

carboplatin

To determine if treatment with AMG 706 (motesanib diphosphate) in combination with paclitaxel and carboplatin improves overall survival compared to treatment with placebo in combination with paclitaxel and carboplatin in subjects with advanced non-squamous NSCLC and in subjects with adenocarcinoma histology (adenocarcinoma subpopulation).

MONET1-MOtesanib NSCLC Efficacy and Tolerability Study

A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-small Cell Lung Cancer.

Takeda

Amgen

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
MONET1-MOtesanib NSCLC Efficacy and Tolerability Study	NCT00460317	Non-Small Cell ...	AMG 706 placebo paclitaxel carboplatin	18 Years -	Amgen
MONET1-MOtesanib NSCLC Efficacy and Tolerability Study	NCT00460317	Non-Small Cell ...	AMG 706 placebo paclitaxel carboplatin	18 Years -	Amgen

Spots Global Cancer Trial Database for multi kinase inhibitor